JP2004527206A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527206A5
JP2004527206A5 JP2001582388A JP2001582388A JP2004527206A5 JP 2004527206 A5 JP2004527206 A5 JP 2004527206A5 JP 2001582388 A JP2001582388 A JP 2001582388A JP 2001582388 A JP2001582388 A JP 2001582388A JP 2004527206 A5 JP2004527206 A5 JP 2004527206A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
group
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001582388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/015043 external-priority patent/WO2001085789A2/en
Publication of JP2004527206A publication Critical patent/JP2004527206A/ja
Publication of JP2004527206A5 publication Critical patent/JP2004527206A5/ja
Pending legal-status Critical Current

Links

JP2001582388A 2000-05-10 2001-05-09 Rykタンパク質を使用する新脈管形成の調節方法 Pending JP2004527206A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10
PCT/US2001/015043 WO2001085789A2 (en) 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis

Publications (2)

Publication Number Publication Date
JP2004527206A JP2004527206A (ja) 2004-09-09
JP2004527206A5 true JP2004527206A5 (de) 2008-06-26

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001582388A Pending JP2004527206A (ja) 2000-05-10 2001-05-09 Rykタンパク質を使用する新脈管形成の調節方法

Country Status (13)

Country Link
EP (1) EP1287121A2 (de)
JP (1) JP2004527206A (de)
AR (1) AR028424A1 (de)
AU (1) AU2001261343A1 (de)
CA (1) CA2408349A1 (de)
CO (1) CO5300464A1 (de)
DO (1) DOP2001000164A (de)
EC (1) ECSP014068A (de)
GT (1) GT200100079A (de)
PE (1) PE20011218A1 (de)
SV (1) SV2002000442A (de)
UY (1) UY26696A1 (de)
WO (1) WO2001085789A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066087A2 (en) * 2002-02-06 2003-08-14 Developgen Aktiengesellschaft Für Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
NZ300808A (en) * 1994-12-23 1999-04-29 Ludwig Inst Cancer Res A method of detecting a ligand capable of binding the receptor protein nyk
ATE321856T1 (de) * 1998-06-11 2006-04-15 Humane rezeptortyrosinkinase
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4

Similar Documents

Publication Publication Date Title
JP4881433B2 (ja) 治療薬の薬物動態の調整
JP2002503641A5 (de)
JP2004511201A5 (de)
ATE331031T1 (de) Peptidfragment des g-proteins des respiratorischen syncytialvirus, immunogene verbindung und pharmazeutische zusammensetzung, die es enthalten, und herstellungsverfahren
JP2009542696A5 (de)
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
JP2009537143A5 (de)
JP2008529558A5 (de)
WO2004062556A8 (en) Methods for preventing and treating alzheimer’s disease (ad)
JP2002206000A5 (de)
JP2003510050A5 (de)
JP2005237328A5 (de)
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
CA2329800A1 (en) Protein formulations
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
EP1600441A3 (de) Krystalline form von Lercanipidin hydrochlorid und Verfahren zu dessen Herstellung
JP2002525081A5 (de)
CA2470731A1 (en) Corticotropin releasing factor 2 receptor agonists
JP2004527206A5 (de)
JP2002540769A5 (de)
WO1999014345A3 (de) Arzneimittel zur therapie einer manifesten lyme-borreliose
JP2002533115A5 (de)
JP2004508843A5 (de)
WO2002004487A3 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
JP2007536910A5 (de)